Literature DB >> 35364234

Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future.

L C Ardolino1, R Dear2, A J Armstrong3, S Gillessen4, A M Joshua5.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35364234      PMCID： PMC9211017          DOI： 10.1016/j.annonc.2022.03.272

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   51.769


× No keyword cloud information.
  16 in total

1.  Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

Authors:  Mario Eisenberger; Anne-Claire Hardy-Bessard; Choung Soo Kim; Lajos Géczi; Daniel Ford; Loïc Mourey; Joan Carles; Phillip Parente; Albert Font; Gabriel Kacso; Mustapha Chadjaa; Wenping Zhang; John Bernard; Johann de Bono
Journal:  J Clin Oncol       Date:  2017-08-15       Impact factor: 44.544

2.  Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.

Authors:  Daniel J George; Oliver Sartor; Kurt Miller; Fred Saad; Bertrand Tombal; Ján Kalinovský; Xiaolong Jiao; Krishna Tangirala; Cora N Sternberg; Celestia S Higano
Journal:  Clin Genitourin Cancer       Date:  2020-01-07       Impact factor: 2.872

3.  The Wild West of Checkpoint Inhibitor Development.

Authors:  Julia A Beaver; Richard Pazdur
Journal:  N Engl J Med       Date:  2021-12-15       Impact factor: 91.245

4.  Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Authors:  Arun A Azad; Bernhard J Eigl; R Nevin Murray; Christian Kollmannsberger; Kim N Chi
Journal:  Eur Urol       Date:  2014-07-10       Impact factor: 20.096

5.  Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

Authors:  Karim Fizazi; Christophe Massard; Petri Bono; Robert Jones; Vesa Kataja; Nicholas James; Jorge A Garcia; Andrew Protheroe; Teuvo L Tammela; Tony Elliott; Leena Mattila; John Aspegren; Annamari Vuorela; Peter Langmuir; Mika Mustonen
Journal:  Lancet Oncol       Date:  2014-06-25       Impact factor: 41.316

6.  Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.

Authors:  Talal Hilal; Mohamad Bassam Sonbol; Vinay Prasad
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

7.  Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Authors:  D Bianchini; D Lorente; A Rodriguez-Vida; A Omlin; C Pezaro; R Ferraldeschi; A Zivi; G Attard; S Chowdhury; J S de Bono
Journal:  Eur J Cancer       Date:  2013-09-25       Impact factor: 9.162

8.  KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer.

Authors:  Julie N Graff; Li Wen Liang; Jeri Kim; Arnulf Stenzl
Journal:  Future Oncol       Date:  2021-05-28       Impact factor: 3.404

9.  Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.

Authors:  Gerhardt Attard; Michael Borre; Howard Gurney; Yohann Loriot; Corina Andresen-Daniil; Ranjith Kalleda; Trinh Pham; Mary-Ellen Taplin
Journal:  J Clin Oncol       Date:  2018-07-20       Impact factor: 44.544

10.  Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?

Authors:  Daniel H Kwon; Christopher M Booth; Vinay Prasad
Journal:  Eur Urol       Date:  2021-03-12       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.